Isosorbide

Isosorbide

SCHEMBL4353400

O=[N+]([O-])O.O=[N+]([O-])O.O=[N+]([O-])O.O[C@@H]1CO[C@H]2[C@@H]1OC[C@@H]2O

nearest known ligand 0.65

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ERG11

The experimentally established mechanism targets of Isosorbide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.65
LMNA P02545 1/20 0.65
MAPT P10636 1/20 0.62
ALDH1A1 P00352 1/20 0.41
CA5A P35218 1/20 0.40
CA5B Q9Y2D0 1/20 0.40
GSR P00390 3/20 0.33
BCHE P06276 3/20 0.33
CA2 P00918 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Isosorbide SCHEMBL3388024 1.00 THRB (0.65) THRBLMNAMAPTALDH1A1CA5A
Isosorbide SCHEMBL217707 1.00 THRB (0.65) THRBLMNAMAPTALDH1A1CA5A
Isosorbide SCHEMBL2129898 1.00 THRB (0.65) THRBLMNAMAPTALDH1A1CA5A
Isosorbide SCHEMBL5699287 1.00 THRB (0.65) THRBLMNAMAPTALDH1A1CA5A
Isosorbide SCHEMBL5170125 1.00 THRB (0.65) THRBLMNAMAPTALDH1A1CA5A
Isosorbide SCHEMBL27944142 0.90 THRB (0.65) THRBLMNAMAPTALDH1A1GSR
Isosorbide SCHEMBL8414428 0.84 THRB (0.56) THRBLMNAMAPTALDH1A1GSR
Isosorbide Mononitrate SCHEMBL919022 0.83 MAPT (0.93) THRBLMNAMAPTALDH1A1GSR
Isosorbide SCHEMBL24465084 0.81 THRB (1.00) THRBLMNAMAPTBCHE
Isosorbide SCHEMBL6298736 0.81 THRB (1.00) THRBLMNAMAPTBCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040063684-A1 Treatment of oesophageal motility disorders and gastro-oesophageal reflux disease KAMM MICHAEL A (GB) 2004-04-01 US claimed
EP-1357905-A2 A TREATMENT OF OESOPHAGEAL MOTILITY DISORDERS AND GASTRO-OESOPHAGEAL REFLUX DISEASE Kamm, Michael Albert (GB) 2003-11-05 EP claimed
WO-2002062324-A2 A TREATMENT OF OESOPHAGEAL MOTILITY DISORDERS AND GASTRO-OESOPHAGEAL REFLUX DISEASE KAMM MICHAEL ALBERT (GB) 2002-08-15 WO claimed
US-11166931-B2 Induction of arteriogenesis with an NO (nitric oxide) donor G. POHL-BOSKAMP GMBH & CO. KG (DE) 2021-11-09 US disclosed
EP-2877170-B1 INDUCTION OF ARTERIOGENESIS WITH NITROGLYCERINE G POHL BOSKAMP GMBH & CO KG (DE) 2019-04-10 EP disclosed
EP-3412285-A2 INDUCTION OF ARTERIOGENESIS G. Pohl-Boskamp GmbH & Co. KG (DE) 2018-12-12 EP disclosed
US-20170172966-A1 INDUCTION OF ARTERIOGENESIS WITH AN NO (NITRIC OXIDE) DONOR G. POHL-BOSKAMP GMBH & CO. KG (DE) 2017-06-22 US disclosed
US-20150164845-A1 INDUCTION OF ARTERIOGENESIS WITH AN NO (NITRIC OXIDE) DONOR POHL BOSKAMP G GMBH & CO KG (DE) 2015-06-18 US disclosed
EP-2877170-A1 INDUCTION OF ARTERIOGENESIS WITH AN NO (NITRIC OXIDE) DONOR G. Pohl-Boskamp GmbH & Co. KG (DE) 2015-06-03 EP disclosed
US-20150025060-A1 Foamable Compositions and Kits Comprising One or More of a Channel Agent, a Cholinergic Agent, A nitric Oxide Donor and Related Agents and Their Uses FOAMIX LTD. (IL) 2015-01-22 US disclosed
WO-2013178715-A1 INDUCTION OF ARTERIOGENESIS WITH AN NO (NITRIC OXIDE) DONOR G. POHL-BOSKAMP GMBH & CO. KG (DE) 2013-12-05 WO disclosed
WO-2008110872-A2 FOAMABLE COMPOSITIONS AND KITS COMPRISING ONE OR MORE OF A CHANNEL AGENT, A CHOLINERGIC AGENT, A NITRIC OXIDE DONOR, AND RELATED AGENTS AND THEIR USES FOAMIX LTD. (US) 2008-09-18 WO disclosed
US-20050070607-A1 N-acetylcysteine compositions and methods for the treatment and prevention of cysteine/glutathione deficiency in diseases and conditions ANDRUS JAMES (US) 2005-03-31 US disclosed
EP-1351698-A4 HERBAL COMPOSITION FOR ANGINA PECTORIS, METHOD TO PREPARE SAME AND USES THEREOF TIANJIN TASLY PHARMACEUTICAL (CN) 2004-11-03 EP disclosed
US-20040063684-A1 Treatment of oesophageal motility disorders and gastro-oesophageal reflux disease KAMM MICHAEL A (GB) 2004-04-01 US disclosed
EP-1357905-A2 A TREATMENT OF OESOPHAGEAL MOTILITY DISORDERS AND GASTRO-OESOPHAGEAL REFLUX DISEASE Kamm, Michael Albert (GB) 2003-11-05 EP disclosed
EP-1351698-A2 HERBAL COMPOSITION FOR ANGINA PECTORIS, METHOD TO PREPARE SAME AND USES THEREOF Tianjin Tasly Pharmaceutical Co., Ltd., China (CN) 2003-10-15 EP disclosed
US-20030152651-A1 Herbal composition for angina pectoris, method to prepare same and uses thereof TIANJIN TASLY PHARMACEUTICAL CO., LTD., CHINA 2003-08-14 US disclosed
WO-2002062324-A2 A TREATMENT OF OESOPHAGEAL MOTILITY DISORDERS AND GASTRO-OESOPHAGEAL REFLUX DISEASE KAMM MICHAEL ALBERT (GB) 2002-08-15 WO disclosed
WO-2002058625-A2 HERBAL COMPOSITION FOR ANGINA PECTORIS, METHOD TO PREPARE SAME AND USES THEREOF TIANJIN TASLY PHARMACEUTICAL CO., LTD., CHINA (CN) 2002-08-01 WO disclosed